Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025

New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors.

View Full Paper
Ask AI
Bookmark
Share

Authors

YUYutaka Ueda

Discussion

Loading...

Member takes

Overview

Novel complement inhibitors improve anemia and management of paroxysmal nocturnal hemoglobinuria, suggesting better patient outcomes.

Key Points

  • Eculizumab improves prognosis by blocking intravascular hemolysis and is a primary treatment for PNH.
  • Pegcetacoplan, a C3 inhibitor, has been shown to improve anemia better than Ecu in PNH patients.
  • Proximal complement inhibitors can enhance anemia control but carry a risk of breakthrough hemolysis.
  • Future therapies must focus on controlling persistent anemia and improving the quality of life for patients with PNH.

Cite This Study

Yutaka Ueda (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64787e9ehttps://doi.org/10.11406/rinketsu.66.756
View Full Paper
Ask AI
Bookmark
Share